Alkermes plc - Ordinary Shares (ALKS)

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.

A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center.

Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes.

Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulness and sleepiness scores.

Alkermes (ALKS) Q3 2025 earnings crush estimates with a 58% EPS beat and $394.2M revenue. The company raises its full-year 2025 financial guidance.

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors.

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.

DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to its investors.

The companies are both working in the sleep space, focusing on excessive daytime sleepiness.

Alkermes will buy Avadel for up to $20 per share.

Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.